The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).

Check the time stamp on this data. Updated AI-Generated Signals for Zai Lab Limited (ZLAB) available here: ZLAB. Type a few symbols and Take a Trial. The signals for these will appear immediately on ...

Chorus Aviation Inc. ("Chorus") today announced the results of its previously announced offers to purchase the outstanding 6.00% Convertible Senior Unsecured Debentures due June 30, 2026 (the "Series ...

Fidelity Investments Canada ULC (Fidelity) today launched three new products built on Fidelity's robust quantitative and fundamental research.New quantitative funds Fidelity Absolute Income Fund ?

This page features the latest news about the Zai Lab stock. Zai Lab Limited Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 Zai Lab (NASDAQ:ZLAB) Limited (ZLAB; HKEX: 9688 ...